Profile data is unavailable for this security.
About the company
C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Company’s pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.
- Revenue in GBP (TTM)24.68m
- Net income in GBP10.57m
- Incorporated2014
- Employees49.00
- LocationC4X Discovery Holdings PLCManchester One, 53 Portland StreetMANCHESTER M1 3LDUnited KingdomGBR
- Phone+44 161 235 5085
- Websitehttps://www.c4xdiscovery.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synairgen plc | 0.00 | -9.99m | 12.99m | 30.00 | -- | 0.8136 | -- | -- | -0.0496 | -0.0496 | 0.00 | 0.0793 | 0.00 | -- | -- | 0.00 | -41.40 | -54.75 | -48.86 | -60.72 | -- | -- | -- | -83,247.62 | -- | -- | 0.00 | -- | -- | -- | 63.74 | -- | 0.00 | -- |
| Provexis plc | 598.08k | -496.59k | 14.71m | 2.00 | -- | 14.67 | -- | 24.59 | -0.0002 | -0.0002 | 0.0003 | 0.0004 | 0.6717 | 3.04 | 2.95 | 299,040.00 | -55.78 | -48.82 | -41.86 | -33.68 | 46.72 | 86.14 | -83.03 | -97.64 | 1.96 | -- | 0.00 | -- | -8.51 | 10.58 | -71.79 | -- | -- | -- |
| Genincode PLC | 1.72m | -6.73m | 15.48m | 28.00 | -- | 1.76 | -- | 9.02 | -0.0703 | -0.0703 | 0.0179 | 0.0497 | 0.168 | 16.36 | 2.88 | 61,285.71 | -65.92 | -- | -72.37 | -- | 47.55 | -- | -392.31 | -- | 5.85 | -- | 0.0632 | -- | 23.92 | -- | -34.21 | -- | -- | -- |
| Chill Brands Group PLC | 146.62k | -3.64m | 16.17m | 2.00 | -- | -- | -- | 110.30 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Destiny Pharma PLC | 0.00 | -5.97m | 17.39m | 20.00 | -- | 1.46 | -- | -- | -0.0759 | -0.0759 | 0.00 | 0.1251 | 0.00 | -- | -- | 0.00 | -48.68 | -47.98 | -52.87 | -52.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.80 | -- | -45.97 | -- |
| OptiBiotix Health PLC | 689.10k | -13.17m | 17.63m | 3.00 | -- | 1.75 | -- | 25.58 | -0.1489 | -0.1489 | 0.0078 | 0.1029 | 0.0426 | 2.28 | 1.25 | 229,700.00 | -81.35 | 17.83 | -83.43 | 18.66 | 49.31 | 54.87 | -1,911.88 | 190.54 | 3.24 | -0.089 | 0.00 | -- | -79.35 | 19.05 | -58.68 | 6.28 | 30.03 | -- |
| LungLife AI Inc | 36.96k | -4.35m | 18.67m | 19.00 | -- | 1.24 | -- | 505.11 | -0.1707 | -0.1707 | 0.0015 | 0.2495 | 0.0038 | -- | 0.1474 | 1,945.24 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Verici DX PLC | 15.27k | -9.01m | 19.37m | 14.00 | -- | 2.53 | -- | 1,268.78 | -0.0529 | -0.0529 | 0.00009 | 0.0316 | 0.0013 | -- | 0.1152 | 1,017.73 | -77.76 | -- | -92.28 | -- | 84.21 | -- | -59,015.79 | -- | -- | -- | 0.0232 | -- | -- | -- | -36.94 | -- | -- | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 19.54m | 11.00 | -- | 5.08 | -- | 120.86 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| Oncimmune Holdings PLC | -100.00bn | -100.00bn | 19.57m | 56.00 | -- | -- | -- | -- | -- | -- | -- | -0.0866 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3169 | -- | 2.39 | -- | -- | -- | -- | -- | -- | -- |
| Sareum Holdings Plc | 0.00 | -4.26m | 20.21m | 5.00 | -- | 34.54 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.17m | 21.47m | 14.00 | -- | 4.99 | -- | -- | -0.007 | -0.007 | 0.00 | 0.0032 | 0.00 | -- | -- | 0.00 | -95.17 | -73.59 | -107.02 | -86.78 | -- | -- | -- | -- | -- | -71.62 | 0.4735 | -- | -- | -- | 21.96 | -- | 46.18 | -- |
| C4X Discovery Holdings PLC | 24.68m | 10.57m | 22.07m | 49.00 | 2.09 | 0.897 | 2.02 | 0.8942 | 0.0419 | 0.0419 | 0.0979 | 0.0976 | 1.18 | -- | 5.02 | 503,673.50 | 50.37 | -66.17 | 55.00 | -76.79 | 99.94 | 97.43 | 42.81 | -416.04 | -- | -- | 0.0104 | -- | -36.64 | -24.70 | -36.16 | -- | -16.37 | -- |
| Oxford Biodynamics PLC | 510.00k | -10.83m | 27.76m | 45.00 | -- | 2.97 | -- | 54.42 | -0.0729 | -0.0729 | 0.0035 | 0.0299 | 0.0371 | 0.7987 | 0.332 | 11,333.33 | -78.82 | -39.72 | -105.32 | -45.52 | 52.16 | -- | -2,122.75 | -1,324.62 | 1.72 | -7.50 | 0.5154 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
| Science in Sport PLC | 65.93m | -7.07m | 28.71m | 158.00 | -- | 0.7213 | -- | 0.4354 | -0.0464 | -0.0464 | 0.4239 | 0.2184 | 0.8479 | 4.20 | 3.83 | 417,278.50 | -9.09 | -9.69 | -13.75 | -11.97 | 41.88 | 47.09 | -10.72 | -11.94 | 0.6921 | -2.31 | 0.2825 | -- | 1.97 | 32.50 | -96.47 | -- | 49.81 | -- |
| CRUSHMETRIC Group Ltd | 399.93k | -882.98k | 30.00m | 20.00 | -- | 1.17 | -- | 75.01 | -0.0072 | -0.0072 | 0.0028 | 0.1066 | 0.0255 | 7.14 | 2.64 | 19,996.45 | -5.72 | -40.65 | -8.35 | -- | 34.66 | 37.39 | -224.56 | -140.54 | 0.072 | -14.42 | 0.0558 | -- | 119.19 | -1.40 | -7.26 | -- | 12.11 | -- |
Data as of Apr 18 2024. Currency figures normalised to C4X Discovery Holdings PLC's reporting currency: UK Pound GBX
52.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Capital LLPas of 31 Oct 2023 | 45.00m | 17.84% |
| Lombard Odier Asset Management (Europe) Ltd.as of 03 Jan 2024 | 41.80m | 16.57% |
| Baillie Gifford & Co.as of 31 Jul 2021 | 14.31m | 5.68% |
| Canaccord Genuity Wealth Ltd.as of 05 Nov 2021 | 7.75m | 3.07% |
| Legal & General Investment Management Ltd.as of 07 Sep 2020 | 6.15m | 2.44% |
| Investec Wealth & Investment Ltd.as of 01 Mar 2024 | 6.15m | 2.44% |
| Herald Investment Management Ltd.as of 11 Nov 2020 | 6.13m | 2.43% |
| City Financial Investment Co. Ltd.as of 31 Jul 2018 | 2.17m | 0.86% |
| Rathbones Investment Management Ltd.as of 01 Mar 2024 | 1.63m | 0.65% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Mar 2024 | 1.54m | 0.61% |
More ▼
Data from 02 Oct 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
